Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Inventory (2023 - 2025)

Historic Inventory for Iovance Biotherapeutics (IOVA) over the last 3 years, with Q3 2025 value amounting to $51.7 million.

  • Iovance Biotherapeutics' Inventory changed N/A to $51.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.7 million, marking a year-over-year change of. This contributed to the annual value of $51.5 million for FY2024, which is 39672.19% up from last year.
  • Latest data reveals that Iovance Biotherapeutics reported Inventory of $51.7 million as of Q3 2025.
  • Iovance Biotherapeutics' 5-year Inventory high stood at $65.5 million for Q1 2025, and its period low was $9.2 million during Q3 2023.
  • Moreover, its 3-year median value for Inventory was $33.7 million (2024), whereas its average is $33.2 million.
  • In the last 5 years, Iovance Biotherapeutics' Inventory surged by 39672.19% in 2024 and then skyrocketed by 27205.54% in 2025.
  • Iovance Biotherapeutics' Inventory (Quarter) stood at $10.4 million in 2023, then surged by 396.72% to $51.5 million in 2024, then increased by 0.37% to $51.7 million in 2025.
  • Its Inventory stands at $51.7 million for Q3 2025, versus $49.8 million for Q2 2025 and $65.5 million for Q1 2025.